What the FDA labels say about taking them together
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide and levonorgestrel
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide's FDA label of February 3, 2025 names levonorgestrel in its drug interactions section; the levonorgestrel labels PlainMeds reads (4) do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide. The cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label: “… contraceptives or oral contraceptives containing progestogens other than drospirenone, levonorgestrel, or norgestimate has not been studied; …”
Check it at the source: the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide FDA label on DailyMed (effective February 3, 2025, Gilead Sciences, Inc.); the levonorgestrel FDA label on DailyMed (effective January 31, 2023, Foundation Consumer Healthcare LLC).
What does the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label say about levonorgestrel?
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label, drug interactionsConcomitant Drug Class/Drug Name: Hormonal Contraceptives: drospirenone/ethinyl estradiol levonorgestrel norgestimate/ethinyl estradiol; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ drospirenone ↑ norgestimate ↑ levonorgestrel ↓ ethinyl estradiol; Clinical Comment: Additional or alternative non-hormonal forms of contraception should be considered when estrogen based contraceptives are coadministered with GENVOYA. Plasma concentrations of drospirenone may be increased when coadministered with cobicistat-containing products. Clinical monitoring is recommended due to the potential for hyperkalemia. …
Source: FDA drug label (Genvoya), Gilead Sciences, Inc., effective February 3, 2025 (SPL set 34784acf-15ed-4715-b504-eb30430518e9), via openFDA; the full label on DailyMed
What does the levonorgestrel label say about cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide?
Levonorgestrel's label (effective January 31, 2023) and its 3 other brand-application labels do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Plan B One-Step), Foundation Consumer Healthcare LLC, effective January 31, 2023 (SPL set 6ce6b40e-14ac-47bd-a648-ddf9e452e559), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | Levonorgestrel | |
|---|---|---|
| Labeled for | HIV | Birth control |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $143.35 per tablet Genvoya tablet | $6.33 per tablet 1.5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once